Naloxone Accord (Naloxone Hydrochloride)

Naloxone Hydrochloride works as a competitive antagonist at mu‑opioid receptors. By binding to these receptors without activating them, it displaces opioid agonists such as morphine or fentanyl, thereby reversing opioid‑induced respiratory depression, sedation and analgesia within minutes after intravenous injection.

The appropriate dose of Naloxone Accord is determined by the prescribing clinician based on the severity of the overdose and the patient’s response. Dosing is individualized, and the prescriber may repeat the dose if the opioid effect persists.

Data on the use of naloxone during pregnancy and lactation are limited. Because the drug can rapidly reverse opioid toxicity, it may be used when the benefit outweighs potential risk. Clinicians should evaluate each case and consider alternative therapies if appropriate.

To order Naloxone Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Naloxone is a short‑acting opioid antagonist that works within minutes and is ideal for emergency reversal of overdose. Compared with longer‑acting agents such as naltrexone, naloxone’s rapid onset and brief duration make it preferable for acute situations, while naltrexone is used for maintenance therapy after detoxification.

Naloxone Accord should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from direct light, moisture and extreme temperatures. Do not freeze the solution, and keep the vial sealed until use to maintain sterility.

Naloxone Accord is administered by intravenous injection. The vial is reconstituted according to the manufacturer’s instructions and injected directly into a vein. Administration should be performed by trained healthcare personnel, with continuous monitoring of the patient’s respiratory and cardiovascular status.

The most serious risks include severe hypertension, cardiac arrhythmias, pulmonary edema, seizures and precipitated acute opioid withdrawal, which can be life‑threatening in patients dependent on opioids. Immediate medical supervision is required to manage these potential complications.

Naloxone Accord is contraindicated in individuals with a known hypersensitivity to naloxone or any of its excipients. Patients with severe cardiovascular disease should receive it with caution, and it should only be used when an opioid overdose is suspected.